Pfizer’s Zirabev (biosimilar, bevacizumab) Receives the US FDA’s Approval for Five Types of Cancer

 Pfizer’s Zirabev (biosimilar, bevacizumab) Receives the US FDA’s Approval for Five Types of Cancer

Pfizer’s Zirabev (bevacizumab, biosimilar) Receives the US FDA’s Approval for Five Types of Cancer

Shots:

  • The approval is based on REFLECTIONS B7391003 study results assessing Zirabev vs reference product Avastin, in patients with advanced non-sq NSCLC
  • The study resulted in biosimilarity data, showing clinical equivalence and no clinically meaningful differences with the reference product in patients. Additionally, Zirabev is Pfizer’s second oncology biosimilar following Trazimera (trastuzumab-qyyp)
  • Zirabev (bevacizumab-bvzr) is a mAb inhibits formation of new blood cells (angiogenesis) approved by the US FDA for MCC, unresectable/LA/recurrent or mnon-sq NSCLC, recurrent glioblastoma, mRCC, and persistent, recurrent or metastatic cervical cancer

Click here to read full press release/ article | Ref: Pfizer | Image: The Hans India

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post